Every 10-Q that Doximity, Inc. (DOCS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DOCS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DOCS filings page.
Doximity, Inc. reported solid growth for the quarter ended December 31, 2025. Revenue rose to $185.1 million from $168.6 million, while net income declined to $61.6 million from $75.2 million as operating expenses, including stock-based compensation, increased.
For the first nine months, revenue reached $499.5 million and net income was $176.9 million, both higher than a year earlier. The company generated $216.9 million in operating cash flow, held $64.8 million in cash plus $670.3 million in marketable securities, and spent $342.9 million on share repurchases.
Doximity closed the $36.3 million Pathway Medical acquisition, adding AI-based medical technology and goodwill, and ended with 126 customers generating at least $500,000 of trailing 12‑month subscription revenue, accounting for about 84% of revenue. Net revenue retention was 112%, indicating continued expansion within existing customers.
Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.
Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.